These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

935 related items for PubMed ID: 29206816

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH.
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    BMC Gastroenterol; 2024 Sep 17; 24(1):314. PubMed ID: 39289603
    [Abstract] [Full Text] [Related]

  • 4. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1776-1787. PubMed ID: 37921344
    [Abstract] [Full Text] [Related]

  • 5. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW.
    Inflamm Bowel Dis; 2018 Aug 16; 24(9):2053-2061. PubMed ID: 29668917
    [Abstract] [Full Text] [Related]

  • 6. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
    Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Matuszczyk M, Kierkus J.
    J Pediatr Gastroenterol Nutr; 2024 Jul 16; 79(1):54-61. PubMed ID: 38477410
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ.
    Dig Dis Sci; 2019 Sep 16; 64(9):2478-2488. PubMed ID: 30923985
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, Nielsen A, Rikke Jørgensen T, Qvist N, Munkholm P.
    Scand J Gastroenterol; 2020 Mar 16; 55(3):265-271. PubMed ID: 32116064
    [Abstract] [Full Text] [Related]

  • 11. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.
    J Am Acad Dermatol; 2018 Feb 16; 78(2):383-394. PubMed ID: 29332708
    [Abstract] [Full Text] [Related]

  • 12. Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.
    Kariburyo MF, Xie L, Teeple A, Tan H, Ingham M.
    Adv Ther; 2017 Jun 16; 34(6):1398-1410. PubMed ID: 28484953
    [Abstract] [Full Text] [Related]

  • 13. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease.
    Abadir A, Troia A, Said H, Tarugu S, Billingsley BC, Sairam N, Minchenberg SB, Owings AH, Parker AM, Brousse B, Carlyle A, Owens BR, Hosseini-Carroll P, Galeas-Pena M, Frasca J, Glover SC, Papamichael K, Cheifetz AS.
    Dig Dis Sci; 2024 Aug 16; 69(8):2796-2803. PubMed ID: 38963462
    [Abstract] [Full Text] [Related]

  • 14. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, Rimmer JE, De La Revilla Negro J, Pavey H, Pele L, Brooks J, Moran GW, Irving PM, Limdi JK, Lamb CA, UK IBD BioResource Investigators , Parkes M, Raine T.
    J Crohns Colitis; 2024 Jun 03; 18(6):790-800. PubMed ID: 38041850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
    Cha JM, Park DI, Park SH, Shin JE, Kim WS, Yang SK.
    J Korean Med Sci; 2017 Jan 03; 32(1):85-94. PubMed ID: 27914136
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
    Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, Accomando S, Cottone M, Romano C.
    Clin Res Hepatol Gastroenterol; 2020 Apr 03; 44(2):223-229. PubMed ID: 31204314
    [Abstract] [Full Text] [Related]

  • 20. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom.
    Patel DB, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR.
    Inflamm Bowel Dis; 2021 Oct 18; 27(10):1593-1601. PubMed ID: 33300555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.